Augmented immunity in cancer patients treated with alpha-interferon

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Metastatic colon and breast cancers pose significant treatment challenges.
• Recombinant alpha-interferon (IFN-α) is explored for its immunomodulatory effects in cancer therapy.

Purpose of the Study:

• To evaluate the immunological effects of recombinant IFN-α clone A in patients with metastatic colon or breast cancer.
• To assess changes in natural killer activity, cellular cytotoxicity, tumor growth inhibition, and leukocyte subsets during IFN-α treatment.

Main Methods:

• Thirty patients received intramuscular recombinant IFN-α clone A (9-50 x 10(6) units/sq m, 3 times weekly for up to 4 months).
• Serial monitoring of immunological parameters including natural killer activity, antibody-dependent cellular cytotoxicity, tumor growth inhibition assay, and leukocyte subset quantification.
• Statistical analysis of changes in immune parameters throughout the treatment course.

Main Results:

• Statistically significant increases in tumor growth inhibition (p < 0.03) and T10 marker-bearing cells (p < 0.0001) were observed in the patient population.
• Individual patient data revealed discernible interferon effects on immune activity, though population-wide changes in natural killer activity were inconsistent.
• Two patients exhibiting tumor response showed increased putative tumor immunity.

Conclusions:

• Recombinant IFN-α therapy demonstrably modulates specific immune parameters relevant to cancer treatment.
• The observed increases in tumor growth inhibition and T10 marker expression support IFN-α's role in enhancing anti-tumor immunity.
• These findings may inform the optimization of interferon dosing and scheduling for improved clinical outcomes in metastatic cancers.